UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2022
(Exact Name of Registrant as Specified in Charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices) | |||||||||||
Registrant’s telephone number, including area code: + 353 1 232 2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. | ||||
On May 11, 2022, STERIS plc (the “Company”) issued a press release announcing financial results for the three and twelve month periods ending March 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits:
| Exhibit No. | Description | |||||||||||||
| 99.1 | ||||||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STERIS plc | |||||||||||
| By | /s/ J. Adam Zangerle | ||||||||||
| Name: | J. Adam Zangerle | ||||||||||
| Title: | Senior Vice President, General Counsel & Company Secretary | ||||||||||
Dated: May 11, 2022
| Exhibit 99.1 | ||||||||||||||
STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year
• | Fourth quarter revenue increases 39% as reported; 11% constant currency organic | ||||||||||||||||
• | As reported EPS of $0.52; adjusted EPS of $2.04 | ||||||||||||||||
• | Company provides FY23 Outlook | ||||||||||||||||
DUBLIN, IRELAND - (May 11, 2022) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 fourth quarter ended March 31, 2022. Revenue as reported for the quarter increased 39% to $1.2 billion compared with $873.5 million in the fourth quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 11% for the fourth quarter of fiscal 2022 as compared to the fourth quarter of fiscal 2021.
“We are pleased to end the year with strong performance in the fourth quarter, as our balanced revenue stream continues to deliver solid growth in the current environment,” said Dan Carestio, President and Chief Executive Officer of STERIS. “While supply chain and inflation continue to be a challenge, our teams have worked to address these issues with minimal impact on our ability to serve our Customers. As we look ahead at the new fiscal year, we expect another record year of performance.”
Fourth Quarter and Full Year Operating Results
As reported, net income for the fourth quarter was $52.3 million or $0.52 per diluted share, compared with net income of $87.4 million or $1.02 per diluted share in the fourth quarter of fiscal 2021. Fiscal 2022 fourth quarter was negatively impacted by amortization of acquired intangibles and inventory and property “step up” and one-time expenses associated with acquisitions totaling approximately $198.3 million. Adjusted net income (see Non-GAAP Financial Measures) for the fourth quarter of fiscal 2022 was $205.4 million or $2.04 per diluted share, compared with the previous year’s fourth quarter of $140.3 million or $1.63 per diluted share.
As reported, full year net income was $243.9 million, or $2.48 per diluted share, compared with $397.4 million, or $4.63 per diluted share in fiscal 2021. Fiscal 2022 was negatively impacted by amortization of acquired intangibles and inventory and property “step up” and one-time expenses associated with acquisitions totaling approximately $654.0 million. Adjusted net income for fiscal 2022 was $778.9 million, or $7.92 per diluted share, compared with adjusted net income of $530.2 million, or $6.17 per diluted share in fiscal 2021.
Fourth Quarter Segment Results
Healthcare revenue as reported grew 32% in the quarter to $738.8 million compared with $561.8 million in the fourth quarter of fiscal 2021, with $141.7 million added from acquisitions during the quarter. This performance reflected a 63% increase in consumable revenue, a 21% increase in service revenue and a 17% improvement in capital equipment revenue. Constant currency organic revenue increased 7% for the quarter compared with the prior year quarter. Healthcare operating income was $160.3 million compared with $122.7 million in last year’s fourth quarter. The increase in profitability was primarily due to the benefit of acquired businesses and solid organic volume offset by supply chain and inflationary cost increases.
Fiscal 2022 fourth quarter revenue for Applied Sterilization Technologies (AST) increased 19% as reported to $222.9 million compared with $187.5 million in the same period last year. Constant currency organic revenue increased 22%, driven primarily by increased demand from medical device and biopharma Customers in the quarter compared with the prior year period. Segment operating income was $107.0 million in the fourth quarter of fiscal 2022 compared with operating income of $88.2 million in the same period last year primarily due to increased volume.
Life Sciences fourth quarter revenue as reported grew 15% to $143.3 million compared with $124.2 million in the fourth quarter of fiscal 2021. Growth was driven by a 18% increase in consumable revenue, a 14% improvement in
service revenue and a 13% increase in capital equipment revenue. Constant currency organic revenue increased 12% in the quarter compared with the prior year quarter. Operating income was $57.5 million in the fourth quarter of fiscal 2022 compared with $44.4 million in the prior year’s fourth quarter. The increase in profitability was primarily due to the increase in organic volume and contributions from acquisitions.
Dental fourth quarter revenue as reported was $105.7 million and operating income was $18.8 million. Both metrics were below the Company’s expectations primarily due to COVID-19 impacts on patient volumes during the quarter and higher supply chain and inflationary costs.
Cash Flow
Net cash provided by operations for fiscal 2022 was $684.8 million, compared with $689.6 million in fiscal 2021. Free cash flow (see Non-GAAP Financial Measures) for fiscal 2022 was $399.0 million compared with $450.9 million in the prior year period. The decrease in free cash flow is primarily due to anticipated costs associated with the Cantel Medical acquisition and higher capital spending year-over-year.
Fiscal 2023 Outlook
For fiscal 2023, constant currency organic revenue growth is anticipated to be approximately 11%. As reported revenue is expected to increase approximately 12%, reflecting the net impact of acquisitions and divestitures as well as the anticipated negative impact of foreign currency fluctuations. Adjusted earnings per diluted share are anticipated to be in the range of $8.55 to $8.75. This outlook acknowledges continued supply chain and inflation pressure, an adjusted effective tax rate of 22% and a share count of approximately 101 million diluted shares.
Capital expenditures are anticipated to be approximately $330 million and free cash flow is expected to be approximately $675 million.
Conference Call
As previously announced, STERIS management will host a conference call tomorrow, May 12, 2022 at 10:00 a.m. ET. The conference call can be heard at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 12, 2022, either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 4484654 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally.
About STERIS
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. For more information, visit www.steris.com.
Company Contact:
Julie Winter, Vice President, Investor Relations and Corporate Communications
Julie_Winter@steris.com
Non-GAAP Financial Measures
Adjusted net income, adjusted EBIT, free cash flow and constant currency organic revenue are non-GAAP measures that may be used from time to time and should not be considered replacements for GAAP results. Non-GAAP financial measures are presented in this release with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. The Company believes that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures, provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure.
Adjusted net income excludes the amortization of intangible assets acquired in business combinations, acquisition related transaction costs, integration costs related to acquisitions, redomiciliation and tax restructuring costs, COVID-19 incremental costs, settlement of I.R.S. adjustments related to prior fiscal years, and certain other unusual or non-recurring items. COVID-19 incremental costs include the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. STERIS believes this measure is useful because it excludes items that may not be indicative of or are unrelated to our core operating results and provides a baseline for analyzing trends in our underlying businesses.
The Company defines free cash flow as cash flows from operating activities less purchases of property, plant, equipment and intangibles, plus proceeds from the sale of property, plant, equipment, and intangibles. STERIS believes that free cash flow is a useful measure of the Company’s ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares.
To measure the percentage organic revenue growth, the Company removes the impact of significant acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales, gross profit, operating income, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
The release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described in STERIS’s other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2021 and subsequently filed Quarterly Reports on Form 10-Q. Many of these important factors are outside of STERIS’s control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS’s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products are summaries only and should not be considered the specific terms of the product clearance or literature. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results
to differ materially from those in the forward-looking statements include, without limitation, (a) the impact of the COVID-19 pandemic on STERIS’s operations, supply chain, material and labor costs, performance, results, prospects, or value, (b) STERIS's ability to achieve the expected benefits regarding the accounting and tax treatments of the redomiciliation to Ireland (“Redomiciliation”), (c) operating costs, Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected, (d) STERIS’s ability to successfully integrate the businesses of Cantel Medical into our existing businesses, including unknown or inestimable liabilities, or increases in expected integration costs or difficulties in connection with the integration of Cantel Medical (e) STERIS’s ability to meet expectations regarding the accounting and tax treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility that anticipated benefits resulting from the TCJA will be less than estimated, (f) changes in tax laws or interpretations that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, (g) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (h) the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated, (i) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation any of the same relating to FDA, EPA or other regulatory authorities, government investigations, the outcome of any pending or threatened FDA, EPA or other regulatory warning notices, actions, requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product or service introductions, affect the production, supply and/or marketing of existing products or services or otherwise affect STERIS’s performance, results, prospects or value, (j) the potential of international unrest, economic downturn or effects of currencies, tax assessments, tariffs and/or other trade barriers, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (k) the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s products and services, (l) the possibility of delays in receipt of orders, order cancellations, or delays in the manufacture or shipment of ordered products, due to supply chain issues or otherwise, or in the provision of services, (m) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS’s businesses, industry or initiatives including, without limitation, those matters described in our Annual Report on Form 10-K for the year ended March 31, 2021, and other securities filings, may adversely impact STERIS’s performance, results, prospects or value, (n) the impact on STERIS and its operations, or tax liabilities, of Brexit or the exit of other member countries from the EU, and the Company’s ability to respond to such impacts, (o) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade or tax legislation, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto, (p) the possibility that anticipated financial results or benefits of recent acquisitions, including the acquisition of Cantel Medical and Key Surgical, or of STERIS’s restructuring efforts, or of recent divestitures, including anticipated revenue, productivity improvement, cost savings, growth synergies and other anticipated benefits, will not be realized or will be other than anticipated, (q) the increased level of STERIS’s indebtedness incurred in connection with the acquisition of Cantel Medical limiting financial flexibility or increasing future borrowing costs, (r) rating agency actions or other occurrences that could affect STERIS’s existing debt or future ability to borrow funds at rates favorable to STERIS or at all, (s) the potential impact of the acquisition of Cantel Medical on relationships, including with suppliers, Customers, employees and regulators, and (t) the effects of contractions in credit availability, as well as the ability of STERIS’s Customers and suppliers to adequately access the credit markets when needed.
| STERIS plc | ||||||||||||||||||||||||||
| Consolidated Condensed Statements of Operations | ||||||||||||||||||||||||||
| (In thousands, except per share data) | Three Months Ended March 31, | Twelve Months Ended March 31, | ||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||||||||||||
| Revenues | $ | 1,210,686 | $ | 873,531 | $ | 4,585,064 | $ | 3,107,519 | ||||||||||||||||||
| Cost of revenues | 639,064 | 493,713 | 2,568,702 | 1,764,419 | ||||||||||||||||||||||
| Gross profit | 571,622 | 379,818 | 2,016,362 | 1,343,100 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Selling, general, and administrative | 453,636 | 221,070 | 1,502,752 | 731,320 | ||||||||||||||||||||||
| Research and development | 26,097 | 17,514 | 87,944 | 66,326 | ||||||||||||||||||||||
| Restructuring expenses (credit) | 31 | (3,024) | 48 | (2,914) | ||||||||||||||||||||||
| Total operating expenses | 479,764 | 235,560 | 1,590,744 | 794,732 | ||||||||||||||||||||||
| Income from operations | 91,858 | 144,258 | 425,618 | 548,368 | ||||||||||||||||||||||
| Non-operating expenses, net | 20,394 | 8,555 | 111,115 | 30,835 | ||||||||||||||||||||||
| Income tax expense | 19,411 | 48,961 | 71,633 | 120,663 | ||||||||||||||||||||||
| Net income | $ | 52,053 | $ | 86,742 | $ | 242,870 | $ | 396,870 | ||||||||||||||||||
| Less: Net (loss) attributable to noncontrolling interests | (208) | (701) | (1,018) | (530) | ||||||||||||||||||||||
| Net income attributable to shareholders | $ | 52,261 | $ | 87,443 | $ | 243,888 | $ | 397,400 | ||||||||||||||||||
| Earnings per ordinary share (EPS) data: | ||||||||||||||||||||||||||
| Basic | $ | 0.52 | $ | 1.02 | $ | 2.50 | $ | 4.66 | ||||||||||||||||||
| Diluted | $ | 0.52 | $ | 1.02 | $ | 2.48 | $ | 4.63 | ||||||||||||||||||
| Cash dividends declared per share ordinary outstanding | $ | 0.43 | $ | 0.40 | $ | 1.69 | $ | 1.57 | ||||||||||||||||||
| Weighted average number of shares outstanding used in EPS computation: | ||||||||||||||||||||||||||
| Basic number of shares outstanding | 100,101 | 85,352 | 97,535 | 85,203 | ||||||||||||||||||||||
| Diluted number of shares outstanding | 100,795 | 86,038 | 98,326 | 85,898 | ||||||||||||||||||||||
| STERIS plc | ||||||||||||||
| Consolidated Condensed Balance Sheets | ||||||||||||||
| (in thousands) | ||||||||||||||
| March 31, | March 31, | |||||||||||||
| 2022 | 2021 | |||||||||||||
| (Unaudited) | ||||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 348,320 | $ | 220,531 | ||||||||||
| Accounts receivable, net | 799,041 | 609,406 | ||||||||||||
| Inventories, net | 574,999 | 315,067 | ||||||||||||
| Prepaid expenses and other current assets | 156,637 | 66,750 | ||||||||||||
| Total current assets | 1,878,997 | 1,211,754 | ||||||||||||
| Property, plant, and equipment, net | 1,552,576 | 1,235,400 | ||||||||||||
| Lease right-of-use assets, net | 188,480 | 150,142 | ||||||||||||
| Goodwill and intangibles, net | 7,761,885 | 3,924,455 | ||||||||||||
| Other assets | 70,661 | 52,720 | ||||||||||||
| Total assets | $ | 11,452,599 | $ | 6,574,471 | ||||||||||
| Liabilities and equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 225,737 | $ | 156,950 | ||||||||||
| Other current liabilities | 696,485 | 420,970 | ||||||||||||
| Total current liabilities | 922,222 | 577,920 | ||||||||||||
| Long-term indebtedness | 2,945,481 | 1,650,540 | ||||||||||||
| Other liabilities | 1,040,259 | 454,543 | ||||||||||||
| Total equity | 6,544,637 | 3,891,468 | ||||||||||||
| Total liabilities and equity | $ | 11,452,599 | $ | 6,574,471 | ||||||||||
| STERIS plc | ||||||||||||||
| Segment Data | ||||||||||||||
| (in thousands) | ||||||||||||||
| Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment’s gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments. | ||||||||||||||
| Three Months Ended March 31, | Twelve Months Ended March 31, | |||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Healthcare | $ | 738,841 | $ | 561,808 | 2,845,467 | $ | 1,954,055 | |||||||||||||||||||
| Applied Sterilization Technologies | 222,880 | 187,541 | 852,972 | 685,912 | ||||||||||||||||||||||
| Life Sciences | 143,258 | 124,182 | 524,964 | 467,552 | ||||||||||||||||||||||
| Dental | 105,707 | — | 361,661 | — | ||||||||||||||||||||||
| Total revenues | $ | 1,210,686 | $ | 873,531 | $ | 4,585,064 | $ | 3,107,519 | ||||||||||||||||||
| Operating income (loss): | ||||||||||||||||||||||||||
| Healthcare | $ | 160,281 | $ | 122,708 | 626,098 | $ | 427,089 | |||||||||||||||||||
| Applied Sterilization Technologies | 107,042 | 88,232 | 410,101 | 310,648 | ||||||||||||||||||||||
| Life Sciences | 57,549 | 44,361 | 216,188 | 180,796 | ||||||||||||||||||||||
| Dental | 18,834 | — | 84,441 | — | ||||||||||||||||||||||
| Corporate | (57,598) | (60,690) | (260,059) | (219,153) | ||||||||||||||||||||||
| Total operating income before adjustments | $ | 286,108 | $ | 194,611 | $ | 1,076,769 | $ | 699,380 | ||||||||||||||||||
| Less: Adjustments | ||||||||||||||||||||||||||
Amortization of acquired intangible assets | $ | 174,882 | $ | 21,243 | $ | 366,434 | $ | 83,892 | ||||||||||||||||||
| Acquisition and integration related charges | 38,090 | 21,650 | 205,788 | 35,634 | ||||||||||||||||||||||
| Redomiciliation and tax restructuring costs | 73 | 742 | 301 | 1,592 | ||||||||||||||||||||||
(Gain) on fair value adjustment of acquisition related contingent consideration | (2,350) | — | (2,350) | (500) | ||||||||||||||||||||||
Net (gain) loss on divestiture of businesses | (1,767) | 2,025 | (874) | 2,030 | ||||||||||||||||||||||
| Amortization of inventory and property "step (down) up" to fair value | (14,709) | 2,499 | 81,804 | 5,600 | ||||||||||||||||||||||
| COVID-19 incremental costs | — | 5,333 | — | 25,793 | ||||||||||||||||||||||
| Restructuring charges (credit) | 31 | (3,139) | 48 | (3,029) | ||||||||||||||||||||||
| Total operating income | $ | 91,858 | $ | 144,258 | $ | 425,618 | $ | 548,368 | ||||||||||||||||||
| STERIS plc | ||||||||||||||
| Consolidated Condensed Statements of Cash Flows | ||||||||||||||
| (in thousands) | ||||||||||||||
| Twelve Months Ended March 31, | ||||||||||||||
| 2022 | 2021 | |||||||||||||
| Operating activities: | (Unaudited) | (Unaudited) | ||||||||||||
| Net income | $ | 242,870 | $ | 396,870 | ||||||||||
| Non-cash items | 590,761 | 273,764 | ||||||||||||
| Changes in operating assets and liabilities | (148,820) | 19,006 | ||||||||||||
| Net cash provided by operating activities | 684,811 | 689,640 | ||||||||||||
| Investing activities: | ||||||||||||||
| Purchases of property, plant, equipment, and intangibles, net | (287,563) | (239,262) | ||||||||||||
| Proceeds from the sale of property, plant, equipment, and intangibles | 1,741 | 569 | ||||||||||||
| Proceeds from the sale of businesses | 169,712 | 518 | ||||||||||||
| Purchase of investments | — | (4,400) | ||||||||||||
| Acquisition of businesses, net of cash acquired | (550,449) | (909,192) | ||||||||||||
| Other | — | (2,392) | ||||||||||||
| Net cash used in investing activities | (666,559) | (1,154,159) | ||||||||||||
| Financing activities: | ||||||||||||||
| Proceeds from issuance of senior public notes | 1,350,000 | — | ||||||||||||
| Proceeds from term loans | 650,000 | 550,000 | ||||||||||||
| Payments on term loans | (295,000) | — | ||||||||||||
| Payments on long-term obligations | (721,284) | (35,000) | ||||||||||||
| Payments on convertible debt | (371,361) | — | ||||||||||||
| Payments under credit facilities, net | (240,174) | (30,461) | ||||||||||||
| Deferred financing fees and debt issuance costs | (17,472) | (12,846) | ||||||||||||
| Acquisition related deferred or contingent consideration | (32,679) | (2,395) | ||||||||||||
| Repurchases of ordinary shares | (55,777) | (14,646) | ||||||||||||
| Cash dividends paid to ordinary shareholders | (163,169) | (133,837) | ||||||||||||
| Distributions to noncontrolling interest | (997) | (4,179) | ||||||||||||
| Contributions from noncontrolling interest | 3,672 | 2,258 | ||||||||||||
| Stock option and other equity transactions, net | 10,071 | 26,726 | ||||||||||||
| Net cash provided by financing activities | 115,830 | 345,620 | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | (6,293) | 19,849 | ||||||||||||
| Increase (decrease) in cash and cash equivalents | 127,789 | (99,050) | ||||||||||||
| Cash and cash equivalents at beginning of period | 220,531 | 319,581 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 348,320 | $ | 220,531 | ||||||||||
The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies. | ||||||||||||||
| Twelve Months Ended March 31, | ||||||||||||||
| 2022 | 2021 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||
| Calculation of Free Cash Flow: | ||||||||||||||
| Cash flows from operating activities | $ | 684,811 | $ | 689,640 | ||||||||||
| Purchases of property, plant, equipment, and intangibles, net | (287,563) | (239,262) | ||||||||||||
| Proceeds from the sale of property, plant, equipment, and intangibles | 1,741 | 569 | ||||||||||||
| Free Cash Flow | $ | 398,989 | $ | 450,947 | ||||||||||
| STERIS plc | |||||
| Consolidated Condensed Statements of Cash Flows (Continued) | |||||
| (in thousands) | |||||
| Twelve Months Ended | |||||
| March 31, | |||||
| Calculation of free cash flow for outlook: | 2023 | ||||
| (Outlook)** | |||||
| Cash flows from operating activities | $1,005,000 | ||||
| Purchases of property, plant, equipment, and intangibles, net | (330,000) | ||||
| Free Cash Flow | $675,000 | ||||
| ** All amounts are estimates. | |||||
STERIS plc
Non-GAAP Financial Measures
(in thousands, except per share data)
Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. | ||||||||||||||
Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies. | ||||||||||||||
| To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates. | ||||||||||||||
| Three months ended March 31, (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| As reported, GAAP | Impact of Acquisitions | Impact of Divestitures | Impact of Foreign Currency Movements | GAAP Growth | Organic Growth | Constant Currency Organic Growth | ||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2022 | 2022 | 2022 | |||||||||||||||||||||||||||||||||||||||||||
| Segment revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Healthcare | $ | 738,841 | $ | 561,808 | $ | 141,655 | $ | — | $ | (3,634) | 31.5 | % | 6.3 | % | 6.9 | % | ||||||||||||||||||||||||||||||||||
| Applied Sterilization Technologies | 222,880 | 187,541 | — | — | (4,958) | 18.8 | % | 18.8 | % | 21.5 | % | |||||||||||||||||||||||||||||||||||||||
| Life Sciences | 143,258 | 124,182 | 5,863 | — | (1,764) | 15.4 | % | 10.6 | % | 12.1 | % | |||||||||||||||||||||||||||||||||||||||
| Dental | 105,707 | — | 105,707 | — | — | — | % | — | % | — | % | |||||||||||||||||||||||||||||||||||||||
| Total | $ | 1,210,686 | $ | 873,531 | $ | 253,225 | $ | — | $ | (10,356) | 38.6 | % | 9.6 | % | 10.8 | % | ||||||||||||||||||||||||||||||||||
| Twelve months ended March 31, (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| As reported, GAAP | Impact of Acquisitions | Impact of Divestitures | Impact of Foreign Currency Movements | GAAP Growth | Organic Growth | Constant Currency Organic Growth | ||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2022 | 2022 | 2022 | |||||||||||||||||||||||||||||||||||||||||||
| Segment revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Healthcare | $ | 2,845,467 | $ | 1,954,055 | $ | 668,264 | $ | — | $ | 7,821 | 45.6 | % | 11.4 | % | 11.0 | % | ||||||||||||||||||||||||||||||||||
| Applied Sterilization Technologies | 852,972 | 685,912 | 19,938 | — | 1,996 | 24.4 | % | 21.4 | % | 21.2 | % | |||||||||||||||||||||||||||||||||||||||
| Life Sciences | 524,964 | 467,552 | 23,236 | — | 1,834 | 12.3 | % | 7.3 | % | 6.9 | % | |||||||||||||||||||||||||||||||||||||||
| Dental | 361,661 | — | 361,661 | — | — | — | % | — | % | — | % | |||||||||||||||||||||||||||||||||||||||
| Total | $ | 4,585,064 | $ | 3,107,519 | $ | 1,073,099 | $ | — | $ | 11,651 | 47.5 | % | 13.0 | % | 12.6 | % | ||||||||||||||||||||||||||||||||||
STERIS plc
Non-GAAP Financial Measures (Continued)
(in thousands, except per share data)
| Three months ended March 31, (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit | Income from Operations | Net Income attributable to shareholders | Diluted EPS | |||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||
| GAAP | $ | 571,622 | $ | 379,818 | $ | 91,858 | $ | 144,258 | $ | 52,261 | $ | 87,443 | $ | 0.52 | $ | 1.02 | ||||||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | (8,282) | 40 | 174,882 | 21,243 | ||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and integration related charges | 1,876 | 390 | 38,090 | 21,650 | ||||||||||||||||||||||||||||||||||||||||||||||
| Redomiciliation and tax restructuring costs | — | — | 73 | 742 | ||||||||||||||||||||||||||||||||||||||||||||||
| (Gain) on fair value adjustment of acquisition related contingent consideration | — | — | (2,350) | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Net (gain) loss on divestiture of businesses | — | — | (1,767) | 2,025 | ||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of inventory and property "step (down) up" to fair value | (14,728) | 2,500 | (14,709) | 2,499 | ||||||||||||||||||||||||||||||||||||||||||||||
| COVID-19 incremental costs | — | 4,125 | — | 5,333 | ||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring (credit) charges | — | (115) | 31 | (3,139) | ||||||||||||||||||||||||||||||||||||||||||||||
| Consideration received for pre-acquisitition arrangement | — | (7) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net impact of adjustments after tax* | 153,102 | 52,887 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net EPS impact | 1.52 | 0.61 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted | $ | 550,488 | $ | 386,758 | $ | 286,108 | $ | 194,611 | $ | 205,363 | $ | 140,323 | $ | 2.04 | $ | 1.63 | ||||||||||||||||||||||||||||||||||
* The tax expense includes both the current and deferred income tax impact of the adjustments.
| Twelve months ended March 31, (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit | Income from Operations | Net Income attributable to shareholders | Diluted EPS | |||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||
| GAAP | $ | 2,016,362 | $ | 1,343,100 | $ | 425,618 | $ | 548,368 | $ | 243,888 | $ | 397,400 | $ | 2.48 | $ | 4.63 | ||||||||||||||||||||||||||||||||||
| Adjustments: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 65 | 11,099 | 366,434 | 83,892 | ||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and integration related charges | 8,906 | 702 | 205,788 | 35,634 | ||||||||||||||||||||||||||||||||||||||||||||||
| Redomiciliation and tax restructuring costs | — | — | 301 | 1,592 | ||||||||||||||||||||||||||||||||||||||||||||||
| (Gain) on fair value adjustment of acquisition related contingent consideration | — | — | (2,350) | (500) | ||||||||||||||||||||||||||||||||||||||||||||||
| Net (gain) loss on divestiture of businesses | — | — | (874) | 2,030 | ||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of inventory and property "step up" to fair value | 73,864 | 5,596 | 81,804 | 5,600 | ||||||||||||||||||||||||||||||||||||||||||||||
| COVID-19 incremental costs | — | 20,460 | — | 25,793 | ||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring (credit) charges | — | (115) | 48 | (3,029) | ||||||||||||||||||||||||||||||||||||||||||||||
| Consideration received for pre-acquisitition arrangement | — | (833) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value adjustment related to convertible debt, premium liability | 27,806 | — | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net impact of adjustments after tax* | 507,222 | 133,583 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net EPS impact | 5.44 | 1.54 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted | $ | 2,099,197 | $ | 1,380,842 | $ | 1,076,769 | $ | 699,380 | $ | 778,916 | $ | 530,150 | $ | 7.92 | $ | 6.17 | ||||||||||||||||||||||||||||||||||
* The tax expense includes both the current and deferred income tax impact of the adjustments.
STERIS plc
Non-GAAP Financial Measures (Continued)
(in thousands, except per share data)
| FY 2023 Outlook | Twelve Months | |||||||
| Ended March 31, 2023 | ||||||||
| (Outlook)*** | ||||||||
| Net income per diluted share | $5.57-5.77 | |||||||
| Amortization of acquired intangible assets | 2.85 | |||||||
| Acquisition and integration related charges | 0.13 | |||||||
| Adjusted net income per diluted share | $8.55-$8.75 | |||||||
| *** All amounts are estimates. | ||||||||
| STERIS plc | |||||||||||||||||
| Unaudited Supplemental Financial Data | |||||||||||||||||
| Fourth Quarter Fiscal 2022 | |||||||||||||||||
| For the Periods Ending March 31, 2022 and 2021 | |||||||||||||||||
| FY 2022 | FY 2021 | FY 2022 | FY 2021 | ||||||||||||||
| Total Company Revenues | Q4 | Q4 | YTD | YTD | |||||||||||||
| Consumables | $ | 420,087 | $ | 206,299 | $ | 1,607,101 | $ | 725,951 | |||||||||
| Service | 526,178 | 445,917 | 2,028,783 | 1,663,979 | |||||||||||||
| Total Recurring | $ | 946,265 | $ | 652,216 | $ | 3,635,884 | $ | 2,389,930 | |||||||||
| Capital Equipment | $ | 264,421 | $ | 221,315 | $ | 949,180 | $ | 717,589 | |||||||||
| Total Revenues | $ | 1,210,686 | $ | 873,531 | $ | 4,585,064 | $ | 3,107,519 | |||||||||
| Ireland Revenues | $ | 19,934 | $ | 20,126 | $ | 82,011 | $ | 71,905 | |||||||||
| Ireland Revenues as a % of Total | 2 | % | 2 | % | 2 | % | 2 | % | |||||||||
| United States Revenues | $ | 845,825 | $ | 613,484 | $ | 3,228,864 | $ | 2,227,038 | |||||||||
| United States Revenues as a % of Total | 70 | % | 70 | % | 70 | % | 72 | % | |||||||||
| International Revenues | $ | 344,927 | $ | 239,921 | $ | 1,274,189 | $ | 808,576 | |||||||||
| International Revenues as a % of Total | 28 | % | 27 | % | 28 | % | 26 | % | |||||||||
| Segment Data | FY 2022 | FY 2021 | FY 2022 | FY 2021 | |||||||||||||
| Q4 | Q4 | YTD | YTD | ||||||||||||||
| Healthcare | |||||||||||||||||
| Revenues | |||||||||||||||||
| Consumables | $ | 254,074 | $ | 155,556 | $ | 1,004,605 | $ | 510,946 | |||||||||
| Service | 272,771 | 224,998 | 1,058,357 | 854,245 | |||||||||||||
| Total Recurring | $ | 526,845 | $ | 380,554 | $ | 2,062,962 | $ | 1,365,191 | |||||||||
| Capital Equipment | 211,996 | 181,254 | 782,505 | 588,864 | |||||||||||||
| Total Healthcare Revenues | $ | 738,841 | $ | 561,808 | $ | 2,845,467 | $ | 1,954,055 | |||||||||
| Segment Operating Income | $ | 160,281 | $ | 122,708 | $ | 626,098 | $ | 427,089 | |||||||||
| Applied Sterilization Technologies | |||||||||||||||||
| Applied Sterilization Technologies Revenues | $ | 222,880 | $ | 187,541 | $ | 852,972 | $ | 685,912 | |||||||||
| Segment Operating Income | $ | 107,042 | $ | 88,232 | $ | 410,101 | $ | 310,648 | |||||||||
| Life Sciences | |||||||||||||||||
| Revenues | |||||||||||||||||
| Consumables | $ | 59,985 | $ | 50,743 | $ | 239,365 | $ | 215,005 | |||||||||
| Service | 38,335 | 33,747 | 143,318 | 124,191 | |||||||||||||
| Total Recurring | $ | 98,320 | $ | 84,490 | $ | 382,683 | $ | 339,196 | |||||||||
| Capital Equipment | 44,938 | 39,692 | 142,281 | 128,356 | |||||||||||||
| Total Life Sciences Revenues | $ | 143,258 | $ | 124,182 | $ | 524,964 | $ | 467,552 | |||||||||
| Segment Operating Income | $ | 57,549 | $ | 44,361 | $ | 216,188 | $ | 180,796 | |||||||||
| Total Dental Revenues | $ | 105,707 | $ | — | $ | 361,661 | $ | — | |||||||||
| Segment Operating Income | $ | 18,834 | $ | — | $ | 84,441 | $ | — | |||||||||
| Corporate | |||||||||||||||||
| Operating loss | $ | (57,598) | $ | (60,690) | $ | (260,059) | $ | (219,153) | |||||||||
| Other Data | FY 2022 | FY 2021 | FY 2022 | FY 2021 | |||||||||||||
| Q4 | Q4 | YTD | YTD | ||||||||||||||
| Healthcare Backlog ** | $ | 423,643 | $ | 206,300 | |||||||||||||
| Life Sciences Backlog ** | 104,693 | 79,866 | |||||||||||||||
| Total Backlog ** | $ | 528,336 | $ | 286,166 | |||||||||||||
| GAAP Income Tax Rate | 27.2 | % | 36.1 | % | 22.8 | % | 23.3 | % | |||||||||
| Adjusted Income Tax Rate | 22.8 | % | 25.0 | % | 21.7 | % | 20.7 | % | |||||||||
** Backlog totals exclude Cantel Medical.
| This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt. | ||||||||||||||